Skye Bioscience Investors Get New Class-Action Notices With Jan. 16 Lead-Plaintiff Deadline
The case centers on claims that Skye overstated nimacimab’s efficacy, with a later trial update coinciding with a sharp stock drop.
Overview
- DJS Law Group and The Gross Law Firm issued fresh notices inviting SKYE shareholders to discuss the litigation and potential lead-plaintiff motions.
- The actions target purchases made from November 4, 2024 through October 3, 2025, which the firms identify as the proposed class period.
- Complaints allege Skye made materially false or misleading statements about the clinical, regulatory, and commercial prospects of its antibody nimacimab.
- A October 6, 2025 topline update reported a missed primary endpoint and lower-than-expected drug exposure, and the stock fell about 60% to $1.90 that day.
- Investors have until January 16, 2026 to seek lead-plaintiff status, and the case remains at a pre-certification stage with no determination of liability.